Next Article in Journal
Recent Advances in the Clinical Translation of Silicon Fluoride Acceptor (SiFA) 18F-Radiopharmaceuticals
Previous Article in Journal
Development of Machine Learning Models for Accurately Predicting and Ranking the Activity of Lead Molecules to Inhibit PRC2 Dependent Cancer
Review

Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?

1
1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece
2
Neurology Department, Athens Naval Hospital, 11521 Athens, Greece
3
Neurology Department, 401 Military General Hospital, 11525 Athens, Greece
*
Author to whom correspondence should be addressed.
Academic Editor: Alfredo Berzal-Herranz
Pharmaceuticals 2021, 14(7), 700; https://doi.org/10.3390/ph14070700
Received: 22 June 2021 / Revised: 18 July 2021 / Accepted: 19 July 2021 / Published: 20 July 2021
(This article belongs to the Section Biopharmaceuticals)
Now more than ever is the time of monoclonal antibody use in neurology. In headaches, disease-specific and mechanism-based treatments existed only for symptomatic management of migraines (i.e., triptans), while the standard prophylactic anti-migraine treatments consist of non-specific and repurposed drugs that share limited safety profiles and high risk for interactions with other medications, resulting in rundown adherence rates. Recent advances in headache science have increased our understanding of the role of calcitonin gene relate peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP) pathways in cephalic pain neurotransmission and peripheral or central sensitization, leading to the development of monoclonal antibodies (mAbs) or small molecules targeting these neuropeptides or their receptors. Large scale randomized clinical trials confirmed that inhibition of the CGRP system attenuates migraine, while the PACAP mediated nociception is still under scientific and clinical investigation. In this review, we provide the latest clinical evidence for the use of anti-CGRP in migraine prevention with emphasis on efficacy and safety outcomes from Phase III and real-world studies. View Full-Text
Keywords: calcitonin gene-related peptide; CGRP; erenumab; fremanezumab; galcanezumab; eptinezumab calcitonin gene-related peptide; CGRP; erenumab; fremanezumab; galcanezumab; eptinezumab
Show Figures

Graphical abstract

MDPI and ACS Style

Mavridis, T.; Deligianni, C.I.; Karagiorgis, G.; Daponte, A.; Breza, M.; Mitsikostas, D.D. Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far? Pharmaceuticals 2021, 14, 700. https://doi.org/10.3390/ph14070700

AMA Style

Mavridis T, Deligianni CI, Karagiorgis G, Daponte A, Breza M, Mitsikostas DD. Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far? Pharmaceuticals. 2021; 14(7):700. https://doi.org/10.3390/ph14070700

Chicago/Turabian Style

Mavridis, Theodoros, Christina I. Deligianni, Georgios Karagiorgis, Ariadne Daponte, Marianthi Breza, and Dimos D. Mitsikostas. 2021. "Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?" Pharmaceuticals 14, no. 7: 700. https://doi.org/10.3390/ph14070700

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop